MX2020007619A - Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones. - Google Patents

Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones.

Info

Publication number
MX2020007619A
MX2020007619A MX2020007619A MX2020007619A MX2020007619A MX 2020007619 A MX2020007619 A MX 2020007619A MX 2020007619 A MX2020007619 A MX 2020007619A MX 2020007619 A MX2020007619 A MX 2020007619A MX 2020007619 A MX2020007619 A MX 2020007619A
Authority
MX
Mexico
Prior art keywords
interventions
subject
succinate
levels
reducing
Prior art date
Application number
MX2020007619A
Other languages
English (en)
Inventor
Veledo Sonia Fernández
Perelló Carolina Serena
Ortega Joan Josep Vendrell
Mallafré Victoria Ceperuelo
Manso Enrique Calvo
Original Assignee
Consorcio Centro De Investig Biomedica En Red M P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consorcio Centro De Investig Biomedica En Red M P filed Critical Consorcio Centro De Investig Biomedica En Red M P
Publication of MX2020007619A publication Critical patent/MX2020007619A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a kits adecuados para determinar la razón de bacterias que producen succinato con respecto a bacterias que consumen succinato en una muestra de heces de un sujeto, en particular la razón de (Prevotellaceae + Veillonellaceae) / (Odoribacteriaceae + Clostridiaceae), o para determinar el nivel de succinato en una muestra de líquidos corporales de un sujeto. La invención también se refiere a un método para determinar si una intervención dirigida, encaminada a reducir los niveles de succinato circulante en un sujeto, ha sido eficaz. Finalmente, la invención se refiere a intervenciones dirigidas para su uso en la prevención y/o el tratamiento de una enfermedad asociada con niveles aumentados de succinato circulante en un paciente.
MX2020007619A 2018-01-17 2019-01-17 Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones. MX2020007619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382020 2018-01-17
PCT/EP2019/051157 WO2019141780A1 (en) 2018-01-17 2019-01-17 Targeted interventions directed at reducing the levels of circulating succinate in a subject, and kits and method for determining effectiveness of said interventions

Publications (1)

Publication Number Publication Date
MX2020007619A true MX2020007619A (es) 2020-09-28

Family

ID=61094364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007619A MX2020007619A (es) 2018-01-17 2019-01-17 Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones.

Country Status (8)

Country Link
US (1) US20200347440A1 (es)
EP (1) EP3740593A1 (es)
JP (2) JP2021511055A (es)
CN (1) CN111936639A (es)
AU (1) AU2019209821A1 (es)
CA (1) CA3088834A1 (es)
MX (1) MX2020007619A (es)
WO (1) WO2019141780A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023118460A1 (en) 2021-12-22 2023-06-29 Pharmabiome Ag New biomarker for disorders and diseases associated with intestinal dysbiosis
WO2023194615A1 (en) * 2022-04-07 2023-10-12 Need4Health B.V. Method for determining insulin dosage

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008336A1 (en) * 1998-02-24 2003-01-09 Juni Jack Edward Use of succinate as a diagnostic tool
WO1999042607A1 (en) * 1998-02-24 1999-08-26 The University Of Notre Dame Du Lac Use of succinate as a diagnostic tool
JP2012085552A (ja) * 2010-10-18 2012-05-10 Kao Corp 糖代謝評価方法
JP5883618B2 (ja) * 2011-11-11 2016-03-15 株式会社ヤクルト本社 ファスコラークトバクテリウム属細菌の新規用途
WO2013176774A1 (en) * 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ITMI20131473A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
US9956282B2 (en) * 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
AU2017249159A1 (en) * 2016-04-11 2018-11-29 President And Fellows Of Harvard College Probiotic formulations for improving athletic performance
US20180002741A1 (en) * 2016-07-01 2018-01-04 The United States Of America As Represented By The Department Of Veterans Affairs Method of diagnosis and treating gastrointestinal and neurological diseases associated with species of genus clostridium

Also Published As

Publication number Publication date
US20200347440A1 (en) 2020-11-05
WO2019141780A1 (en) 2019-07-25
AU2019209821A1 (en) 2020-08-27
CN111936639A (zh) 2020-11-13
JP2021511055A (ja) 2021-05-06
JP2024050778A (ja) 2024-04-10
CA3088834A1 (en) 2019-07-25
EP3740593A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
Williams et al. The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
MX371228B (es) Anticuerpos antiperiostina, kits, composiciones y su uso en la medición de periostina total.
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
ZA202110111B (en) Methods and compositions for treating liver disorders
MX2020007619A (es) Intervenciones dirigidas, encaminadas a reducir los niveles de succinato circulante en un sujeto, y kits y metodo para determinar la eficacia de dichas intervenciones.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
WO2020104705A3 (en) Predicting a treatment response in inflammatory bowel disease
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
WO2017214373A8 (en) Diagnostic and therapeutic methods for cancer
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
WO2020209988A3 (en) Diverse marker panel for ptsd diagnosis and treatment
MX2020013100A (es) Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis.
MX2021009247A (es) Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
WO2018176066A3 (en) Cord blood therapy to treat chronic disease caused by l-form bacteria
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
EP2148934A4 (en) MATRIX MARKER MODEL AND METHOD FOR THE TEST AND TREATMENT OF ARTHRITIS AND RELATED DISEASES
MX2021015034A (es) Composiciones de lactobacillus y usos de las mismas.
PH12020551206A1 (en) Farber disease markers and uses thereof